MX2014013613A - Proceso para la elaboracion de undecapeptidos ciclicos. - Google Patents
Proceso para la elaboracion de undecapeptidos ciclicos.Info
- Publication number
- MX2014013613A MX2014013613A MX2014013613A MX2014013613A MX2014013613A MX 2014013613 A MX2014013613 A MX 2014013613A MX 2014013613 A MX2014013613 A MX 2014013613A MX 2014013613 A MX2014013613 A MX 2014013613A MX 2014013613 A MX2014013613 A MX 2014013613A
- Authority
- MX
- Mexico
- Prior art keywords
- leu
- manufacture
- ala
- methyl
- subjected
- Prior art date
Links
- 125000004122 cyclic group Chemical group 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000543 intermediate Substances 0.000 abstract 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 abstract 2
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical group CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 abstract 1
- OLROWHGDTNFZBH-XEMWPYQTSA-N Alisporivir Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O OLROWHGDTNFZBH-XEMWPYQTSA-N 0.000 abstract 1
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 abstract 1
- 108010077895 Sarcosine Proteins 0.000 abstract 1
- 108010058359 alisporivir Proteins 0.000 abstract 1
- 229950004789 alisporivir Drugs 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000007142 ring opening reaction Methods 0.000 abstract 1
- 229940043230 sarcosine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a procesos e intermediarios útiles para la elaboración de undecapéptidos cíclicos, tales como el Alisporivir, un derivado no inmunosupresor de la ciclosporina A. La ciclosporina se acila sobre la cadena lateral de butenil-metil-treonina y luego se somete a una reacción de abertura de anillo (el anillo se abre entre los residuos de sarcosina y de N-metil-leucina). Este intermediario peptídico lineal se somete a una degradación de Edman (remoción del residuo N-terminal) para así proporcionar el segundo intermediario decapeptídico lineal, por ejemplo de la secuencia Val-N(Me)Leu-Ala-Ala-N(Me)Leu-N(Me) Leu-N(Me)Val-N(Me)Bmt-Abu-Sar cuando se inicia desde CsA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644616P | 2012-05-09 | 2012-05-09 | |
| PCT/EP2013/059672 WO2013167703A1 (en) | 2012-05-09 | 2013-05-08 | Process for the manufacture of cyclic undecapeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014013613A true MX2014013613A (es) | 2015-02-12 |
Family
ID=48444372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013613A MX2014013613A (es) | 2012-05-09 | 2013-05-08 | Proceso para la elaboracion de undecapeptidos ciclicos. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20150087808A1 (es) |
| EP (1) | EP2847211A1 (es) |
| JP (3) | JP2015517481A (es) |
| KR (1) | KR20150006435A (es) |
| CN (2) | CN108715606A (es) |
| AR (1) | AR090964A1 (es) |
| AU (2) | AU2013257989A1 (es) |
| BR (1) | BR112014027648A2 (es) |
| CA (1) | CA2868940A1 (es) |
| CL (1) | CL2014003014A1 (es) |
| CO (1) | CO7141428A2 (es) |
| EA (1) | EA024903B1 (es) |
| EC (1) | ECSP14030537A (es) |
| HK (1) | HK1202555A1 (es) |
| IL (1) | IL235428A0 (es) |
| IN (1) | IN2014DN08483A (es) |
| MA (1) | MA20150231A1 (es) |
| MX (1) | MX2014013613A (es) |
| PE (1) | PE20142433A1 (es) |
| PH (1) | PH12014502499A1 (es) |
| SG (1) | SG11201406303XA (es) |
| TN (1) | TN2014000411A1 (es) |
| TW (1) | TW201350508A (es) |
| WO (1) | WO2013167703A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693820A (zh) * | 2014-11-27 | 2016-06-22 | 武汉药明康德新药开发有限公司 | 一种降解环孢菌素a的方法 |
| EP3623378B1 (en) | 2017-05-12 | 2025-07-02 | Chugai Seiyaku Kabushiki Kaisha | Method for producing cyclic organic compound |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT401177B (de) | 1993-10-22 | 1996-07-25 | Biochemie Gmbh | Verfahren zur herstellung von 7-amino-3-cephem-4-carbonsäure-derivaten |
| CA2335903C (fr) * | 1998-07-01 | 2009-11-10 | Debiopharm S.A. | Nouvelle cyclosporine ayant un profil d'activite ameliore |
| DK1150999T3 (da) * | 1999-02-05 | 2006-10-30 | Debiopharm Sa | Cyclosporinderivater og fremgangsmåde til fremstilling deraf |
| CA2444278C (en) * | 2001-04-20 | 2011-11-22 | Debiopharm S.A. | Modified cyclosporine which can be used as a pro-drug and use thereof |
| ES2266564T3 (es) * | 2001-10-19 | 2007-03-01 | Isotechnika Inc. | Sintesis de analogos de cicloporinas. |
| TW200505946A (en) | 2003-04-08 | 2005-02-16 | Hoffmann La Roche | Process for preparation of cyclosporin a analog |
| HRP20110169T1 (hr) * | 2004-10-01 | 2011-04-30 | Debiopharm S.A. | Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c |
| WO2006063470A1 (en) * | 2004-12-17 | 2006-06-22 | Isotechnika Inc. | Metabolites of cyclosporin analogs |
| CA2674296C (en) | 2007-01-04 | 2015-11-24 | Debiopharm Sa | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
| CA2700536A1 (en) | 2007-09-26 | 2009-04-02 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| US7910378B2 (en) * | 2007-12-14 | 2011-03-22 | Siemens Healthcare Diagnostics Inc. | Methods for detection of hydrophobic drugs |
| WO2009098533A1 (en) | 2008-02-08 | 2009-08-13 | Debiopharm Sa | Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy |
| KR20110093858A (ko) | 2008-11-06 | 2011-08-18 | 데비오 레쉑쉐 빠르마슈띠끄 에스.아 | 시클로운데카뎁시펩티드 화합물 및 약제로서 상기 화합물의 용도 |
| CA2748389A1 (en) * | 2008-12-31 | 2010-07-08 | Scynexis, Inc. | Derivatives of cyclosporin a |
| AU2010208071C1 (en) * | 2009-01-30 | 2013-06-20 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis C infection |
| WO2012021796A2 (en) * | 2010-08-12 | 2012-02-16 | S&T Global, Inc. | Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
-
2013
- 2013-05-07 AR ARP130101557A patent/AR090964A1/es unknown
- 2013-05-08 US US14/399,261 patent/US20150087808A1/en not_active Abandoned
- 2013-05-08 IN IN8483DEN2014 patent/IN2014DN08483A/en unknown
- 2013-05-08 AU AU2013257989A patent/AU2013257989A1/en not_active Abandoned
- 2013-05-08 WO PCT/EP2013/059672 patent/WO2013167703A1/en not_active Ceased
- 2013-05-08 MA MA37498A patent/MA20150231A1/fr unknown
- 2013-05-08 TW TW102116414A patent/TW201350508A/zh unknown
- 2013-05-08 CN CN201810575515.2A patent/CN108715606A/zh active Pending
- 2013-05-08 EP EP13722740.1A patent/EP2847211A1/en not_active Withdrawn
- 2013-05-08 EA EA201492036A patent/EA024903B1/ru not_active IP Right Cessation
- 2013-05-08 BR BR112014027648A patent/BR112014027648A2/pt not_active IP Right Cessation
- 2013-05-08 MX MX2014013613A patent/MX2014013613A/es unknown
- 2013-05-08 SG SG11201406303XA patent/SG11201406303XA/en unknown
- 2013-05-08 CN CN201380023760.8A patent/CN104284902A/zh active Pending
- 2013-05-08 HK HK15102858.0A patent/HK1202555A1/xx unknown
- 2013-05-08 KR KR1020147031112A patent/KR20150006435A/ko not_active Withdrawn
- 2013-05-08 JP JP2015510823A patent/JP2015517481A/ja not_active Withdrawn
- 2013-05-08 CA CA2868940A patent/CA2868940A1/en not_active Abandoned
- 2013-05-08 PE PE2014001983A patent/PE20142433A1/es not_active Application Discontinuation
-
2014
- 2014-09-30 TN TNP2014000411A patent/TN2014000411A1/fr unknown
- 2014-10-30 IL IL235428A patent/IL235428A0/en unknown
- 2014-11-07 CL CL2014003014A patent/CL2014003014A1/es unknown
- 2014-11-10 CO CO14248207A patent/CO7141428A2/es unknown
- 2014-11-10 PH PH12014502499A patent/PH12014502499A1/en unknown
- 2014-12-08 EC ECIEPI201430537A patent/ECSP14030537A/es unknown
-
2016
- 2016-06-30 US US15/198,152 patent/US9840534B2/en not_active Expired - Fee Related
- 2016-08-31 AU AU2016222370A patent/AU2016222370B2/en not_active Ceased
-
2017
- 2017-08-29 JP JP2017164867A patent/JP2018035154A/ja not_active Withdrawn
-
2019
- 2019-09-30 JP JP2019179311A patent/JP2020033349A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20142433A1 (es) | 2015-02-02 |
| KR20150006435A (ko) | 2015-01-16 |
| PH12014502499A1 (en) | 2014-12-22 |
| IL235428A0 (en) | 2014-12-31 |
| AR090964A1 (es) | 2014-12-17 |
| EP2847211A1 (en) | 2015-03-18 |
| MA20150231A1 (fr) | 2015-07-31 |
| EA201492036A1 (ru) | 2015-02-27 |
| JP2015517481A (ja) | 2015-06-22 |
| CN108715606A (zh) | 2018-10-30 |
| CL2014003014A1 (es) | 2015-03-06 |
| TW201350508A (zh) | 2013-12-16 |
| CA2868940A1 (en) | 2013-11-14 |
| AU2016222370A1 (en) | 2016-09-15 |
| IN2014DN08483A (es) | 2015-05-08 |
| WO2013167703A9 (en) | 2014-11-20 |
| CO7141428A2 (es) | 2014-12-12 |
| EA024903B1 (ru) | 2016-10-31 |
| JP2020033349A (ja) | 2020-03-05 |
| AU2013257989A1 (en) | 2014-10-23 |
| US9840534B2 (en) | 2017-12-12 |
| HK1202555A1 (en) | 2015-10-02 |
| CN104284902A (zh) | 2015-01-14 |
| AU2016222370B2 (en) | 2017-10-05 |
| ECSP14030537A (es) | 2015-09-30 |
| TN2014000411A1 (en) | 2015-12-21 |
| WO2013167703A1 (en) | 2013-11-14 |
| US20160304554A1 (en) | 2016-10-20 |
| BR112014027648A2 (pt) | 2017-06-27 |
| SG11201406303XA (en) | 2014-11-27 |
| US20150087808A1 (en) | 2015-03-26 |
| JP2018035154A (ja) | 2018-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201490039A1 (ru) | Химерные и гибридные полипептиды фактора viii и способы их применения | |
| AU2017248121A1 (en) | T cell receptors | |
| SG10201807877TA (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| RU2013118446A (ru) | Способ производства дегареликса и его промежуточных соединений | |
| PH12014502499A1 (en) | Process for the manufacture of cyclic undecapeptides | |
| MX2017009595A (es) | Compuestos antisenescentes y usos de los mismos. | |
| Iwasaki et al. | Selective thioether macrocyclization of peptides having the N-terminal 2-chloroacetyl group and competing two or three cysteine residues in translation | |
| SG10201805039UA (en) | Protease resistant peptides | |
| PH12018502465A1 (en) | Mic-1 compounds and use thereof | |
| Degenkolb et al. | Natural cyclopeptaibiotics and related cyclic tetrapeptides: structural diversity and future prospects | |
| MX2019013362A (es) | PÉPTIDOS CÍCLICOS HOMODÉTICOS CON LA INTEGRINA A4ß7 COMO DIANA. | |
| EA201792362A8 (ru) | Композиции и способы для лечения целиакии спру | |
| NZ755628A (en) | Engineered phenylalanine ammonia lyase polypeptides | |
| NZ593204A (en) | Cycloundecadepsipeptide compounds and use of said compounds as a medicament | |
| MX2018014966A (es) | Peptidos monolipidados resistentes a proteasas. | |
| MX2021004879A (es) | Peptido inhibidor de calicreina 5 (klk5). | |
| Buchanan et al. | Natural cyclic peptides: Synthetic strategies and biomedical applications | |
| FR2968303B1 (fr) | Peptides modulateurs du complexe saspase-flg2 | |
| KR20180084352A (ko) | 돌돔 유래의 신규한 피스시딘 펩티드 및 이의 용도 | |
| RU2017122029A (ru) | Новые способы опосредованного ферментами конъюгирования полипептидов с использованием сортазы | |
| MX2012001850A (es) | Abertura de anillo de lactonas y lactamas. | |
| MX2013010539A (es) | Polipeptido que tienen actividad inductora de la defensa contra estres biotico en plantas, secuencia de nucleotidos que lo codifica, microorganismo, composiciones y metodos. | |
| McKinnie et al. | The solid phase supported peptide synthesis of analogues of the lantibiotic lactocin S | |
| Elagawany et al. | An improved route for the synthesis of Rolloamide B | |
| MX2021006809A (es) | Rutas lineales en fase de solucion para hexapeptidos de wnt. |